医学
化疗
胃肠病学
内科学
药品
肝功能
肝损伤
肝癌
肝炎
肝功能检查
癌症
外科
药理学
出处
期刊:Central Plains Medical Journal
日期:2016-11-10
卷期号:43 (21): 39-41
标识
DOI:10.3760/cma.j.issn.1674-4756.2016.21.014
摘要
Objective
To observe the efficacy of magnesium isoglycyrrhizinate combined with ursodesoxycholic acid in prevention of chemotherapy drug-induced liver injury in patients with gastrointesdnal tumors.
Methods
Eighty patients with early stage gastrointesdnal cancer and indications for systemic chemotherapy that had been diagnosed with gastrointestinal malignant tumors by pathology were randomly divided into observation group(n=40)and control group(n=40). The observation group received chemotherapy drugs combined with magnesium isoglycyrrhizinate and ursodesoxycholic acid, and the control group only received chemotherapy drugs combined with magnesium isoglycyrrhizinate.
Results
There were 5 cases(12.5%)with liver injury in the observation group, and 12 cases(30%)in the control group, the difference was statistically significant(P<0.05). The levels of ALT, AST, TBiL, ALP after treatment in observation group were significant lower than those of control group, the difference was statistically significant(P<0.05); and the difference of liver function between before and after treatment in observation group was significant lower than that of control group, the difference was statistically significant(P<0.05).
Conclusions
Magnesium isoglycyrrhizinate combined with ursodesoxycholic acid was effective for the prevention of chemotherapy drug-induced liver damage after initial chemotherapy in patients with early stage gastrointestinal cancer.
Key words:
Magnesium isoglycyrrhizinate; Ursodesoxycholic acid; Hepatitis, toxic; Neoplasms; Drug therapy
科研通智能强力驱动
Strongly Powered by AbleSci AI